<code id='C4E870BF06'></code><style id='C4E870BF06'></style>
    • <acronym id='C4E870BF06'></acronym>
      <center id='C4E870BF06'><center id='C4E870BF06'><tfoot id='C4E870BF06'></tfoot></center><abbr id='C4E870BF06'><dir id='C4E870BF06'><tfoot id='C4E870BF06'></tfoot><noframes id='C4E870BF06'>

    • <optgroup id='C4E870BF06'><strike id='C4E870BF06'><sup id='C4E870BF06'></sup></strike><code id='C4E870BF06'></code></optgroup>
        1. <b id='C4E870BF06'><label id='C4E870BF06'><select id='C4E870BF06'><dt id='C4E870BF06'><span id='C4E870BF06'></span></dt></select></label></b><u id='C4E870BF06'></u>
          <i id='C4E870BF06'><strike id='C4E870BF06'><tt id='C4E870BF06'><pre id='C4E870BF06'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:focus    - browse:36
          Alastair Grant/AP

          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

          advertisement

          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus